Introduction
Alzheimer's disease (AD) is the most common neurodegenerative disorder. AD is characterized by progressive memory and cognitive impairment, and cerebral accumulation of extracellular amyloid plaques and intraneuronal neurofibrillary tangles. [1] The major component of amyloid plaques is amyloid b-protein (Ab), a small protein that exists primarily as 40-or 42-residue polypeptides (Ab40 and Ab42, respectively). Ab42 has been shown to be more neurotoxic than Ab40, [2] and it follows a different pathway of oligomerization. [3, 4] Ab42 is more prone to form high-order oligomers than Ab40, and this tendency correlates with structural stabilization of the C terminus of Ab42 mediated by the presence of isoleucine (I) 41 and alanine (A) 42. [3, [5] [6] [7] Although, the mechanism underlying AD pathology is still unclear, mounting evidence supports a central role for Ab oligomers, particularly those of Ab42, in causing the cognitive impairment seen in AD patients. [8, 9] In view of the critical role of the C-terminal region of Ab42 in self-assembly, previously, we prepared C-terminal fragments (CTFs) of the general formula Ab(x-42), where x is 28 to 39, and tested them as inhibitors of Ab42 assembly and toxicity. [10] Of the 12 CTFs tested, Ab(31-42) was the strongest inhibitor of Ab42-induced toxicity, in assays evaluating both synaptic activity and cell death. [10] It was found to inhibit Ab42-induced neurotoxicity in differentiated rat pheochromocytoma (PC-12) cells with IC 50 values of 14 AE 2 and 20AE 4 mm in the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction and lactate dehydrogenase (LDH) release assays, respectively. In addition, Ab(31-42) rescued mouse primary hippocampal neurons from Ab42-induced inhibition of miniature excitatory postsynaptic current frequency. [10] The second most potent inhibitor was Ab(30-42). A mechanistic investigation showed that both analogues inhibited Ab42 hexamer formation (Ab(31-42) IC 50 = 23 AE 4 mm; Ab(30-42) IC 50 = 0.24 AE 0.03 mm) as determined by photo-induced cross-linking of unmodified proteins, [10] and suppressed formation of larger assemblies with a hydrodynamic radius (R H ) of 20-60 nm detected by dynamic light scattering (DLS). [10, 11] Low solubility is a general issue when working with hydrophobic peptides derived from Ab. Different strategies have been investigated for overcoming difficulties related to low solubility of hydrophobic peptides. For example, Fülçp et al.
Neurotoxic Ab42 oligomers are believed to be the main cause of Alzheimer's disease. Previously, we found that the C-terminal fragments (CTFs), Ab(30-42) and Ab(31-42) were the most potent inhibitors of Ab42 oligomerization and toxicity in a series of Ab(x-42) peptides (x = 28-39). Therefore, we chose these peptides as leads for further development. These CTFs are short (12-13 amino acids) hydrophobic peptides with limited aqueous solubility. Our first attempt to attach hydrophilic groups to the N terminus resulted in toxic peptides. Therefore, we next incorporated N-methyl amino acids, which are known to increase the solubility of such peptides by disrupting the bsheet formation. Focusing on Ab(31-42), we used a two-step N-methyl amino acid substitution strategy to study the structural factors controlling inhibition of Ab42-induced toxicity.
First, each residue was substituted by N-Me-alanine (N-Me-A). In the next step, in positions where substitution produced a significant effect, we restored the original side chain. This strategy allowed exploring the role of both side chain structure and N-Me substitution in inhibitory activity. We found that the introduction of an N-Me amino acid was an effective way to increase both the aqueous solubility and the inhibitory activity of Ab(31-42). In particular, N-Me amino acid substitution at position 9 or 11 increased the inhibitory activity relative to the parent peptide. The data suggest that inhibition of Ab42 toxicity by short peptides is highly structure-specific, providing a basis for the design of new peptidomimetic inhibitors with improved activity, physicochemical properties, and metabolic stability.
introduced an N-terminal arginine (R) residue to Ab(31-34), which was used as a fibrillogenesis inhibitor and showed increased aqueous solubility. [12] Other hydrophilic moieties used for the same purpose include polyethylene glycol (PEG), [13] carbohydrates, [14] and betaine. [15] Taking a different approach, Gordon et al. reported that introduction of N-methyl (N-Me) amino acids increased the solubility of Ab (16) (17) (18) (19) (20) (21) (22) substantially. [16, 17] Using hydrophilic appendages offers a large degree of versatility, exploring different peptidic and nonpeptidic moieties, which can be either charged or neutral. On the other hand, an advantage of N-methylation relative to hydrophilic conjugates is that the molecular weight increase is kept to a minimum. Though N-methylation actually increases the overall hydrophobicity of the resulting derivative, aqueous solubility typically is increased due to prevention of b-sheet formation, particularly of amyloidogenic sequences. [18] Here, to explore structure-activity relationships (SARs), we first synthesized several analogues containing hydrophilic appendages of Ab(30-42) and Ab(31-42). The parent peptides had previously been found to have low aqueous solubility. [19] Based on the results of the initial screening of these analogues, we changed direction and continued to systematically explore Ab(31-42) derivatives containing single N-Me amino acid substitutions, and evaluated their toxicity and inhibitory activity in cell viability assays.
Results and Discussion
Attachment of hydrophilic appendages to CTFs Our initial approach was to attach different hydrophilic moieties to the N terminus of Ab(30-42) or Ab(31-42) in an attempt to improve their aqueous solubility. Several appendages were explored, including neutral and negatively charged amino acids, and PEG (Table 1) . We did not use positively charged residues because Ab(28-42), which contains an N-terminal lysine (K) and was the only positively charged peptide in our original CTF series, was highly toxic. [10] Unfortunately, we found that the new analogues also gained toxicity upon addition of the hydrophilic appendages, regardless of the chemical nature of the hydrophilic moiety ( Figure 1 ). Therefore, we did not continue in this direction and, instead, focused our efforts on a systematic study of N-methylated analogues of Ab(31-42). We chose to focus on Ab(31-42) because it was the strongest inhibitor of toxicity found in the original series. [10] N-Methyl-alanine scanning of Ab(31-42) Alanine (A) scanning is a common method for studying side chain function in bioactive peptides, [20] because A is the smallest chiral amino acid. However, because Ab(31-42) is a hydrophobic peptide with limited aqueous solubility, [19] we suspected that analogues containing single A substitutions might be difficult to synthesize and purify, similar to the parent peptide, [21] and biophysical and biological evaluation of these peptides might be demanding. Therefore, we devised a two-step strategy, in which the first step achieves both a systematic structural study and an increase in aqueous solubility by substituting each residue by N-Me-A. The second step distinguishes between the effects of side chain reduction and N-methylation by reintroducing the side chain in positions showing substantial effects on activity, while keeping the N-Me moiety in that position.
Synthesis of N-methylated Ab(31-42) analogues
We introduced N-Me-A in each position along the Ab(31-42) sequence (Table 2 ) using standard 9-fluorenylmethoxycarbonyl (FMOC) chemistry with 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU) for introduction of N-Me-A itself and the following residue. [22] This protocol allowed successful synthesis of nine out of the twelve N-Me-Acontaining derivatives. However, using this general protocol, we did not obtain correct products for 
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www.chemmedchem.org A8]Ab(31-42) led to products containing deletions of G 7 or of both G 7 and N-Me-A8. These products likely resulted either from a low yield for the N-Me-A8 coupling to V 9 or from formation of a diketopiperzaine (DKP) side product, which is a common problem when proline (P), glycine (G) or N-alkylated amino acids are in the C-terminal dipeptide sequence, or their combinations are in the middle of the sequence, [22] particularly when benzyl alcohol-based solid supports are used. [23] The reaction is both base-and acid-catalyzed and, thus, may occur during coupling, deprotection, and/or cleavage from the solid support. Taking these considerations into account, we increased the coupling time and performed double coupling for G 7 and N-Me-A8. We also reduced the deprotection reaction time to 1-2 min and reduced the cleavage reaction time to 1 hour. Using these modifications, we obtained [N-Me-A8]Ab(31-42) successfully.
For [N-Me-A11]Ab(31-42) and [N-Me-A12]Ab(31-42), due to the proximity of the N-Me amino acid to C-terminal carboxyl group, DKP formation was predicted to occur easily during the synthesis on NovaSyn TGA resin (an alcohol-based solid support). [23] To avoid this side reaction, we used the highly hindered chlorotrityl (Cl-Trt) resin, which had been reported to be an effective way to reduce DKP formation. [23] We also used double coupling and reduced deprotection and cleavage reaction times, resulting in the successful synthesis of these two analogues.
Solubility of N-Me-A-substituted Ab(31-42) analogues
To determine the solubility of N-Me-A-containing analogues, we used a simple filtration assay. [19] Briefly, lyophilized peptides were dissolved or suspended in 10 mm sodium phosphate at 200 mm nominal concentration, sonicated for 1 min, and filtered through a 20 nm pore-size filter to remove insoluble material. Following this treatment, the actual concentrations were determined by amino acid analysis (AAA) and are shown in Table 2 .
Most N-Me-A-substituted analogues of Ab(31-42) had increased solubility relative to that of Ab(31-42)-25 AE 4 mm, except for [N-Me-A1]Ab(31-42), whose solubility was 8 AE 1 mm. The low solubility of [N-Me-A1]Ab(31-42) can be explained by the increase in hydrophobicity, similar to all other analogues, but without disruption of the b-hairpin structure of Ab(31-42), [24] because the methylation is at the N terminus. N-Me-A substitution in positions 8 and 12 also resulted in peptides with relatively low solubility ( Table 2 ), suggesting that N-methylation in these positions did not effectively disrupt the b-hairpin structure. In the case of [N-Me-A12]Ab(31-42), this is likely due to a similar reason as in the case of [N-Me-A1]Ab(31-42), i.e., the N-Me group is too far from the b-strands to disrupt their association. According to the structure of Ab(31-42), calculated based on ion mobility mass spectrometry data, position 8 is located within a b-turn, [24] where N-methylation is unlikely to disrupt the b-hairpin structure. N-Me-A substitution in other positions increased the solubility three-to five-fold, suggesting effective disruption of the b-hairpin structure.
Inhibition of Ab42-induced neurotoxicity by N-Me-Asubstituted Ab(31-42) analogues
As an initial step before testing inhibitory activity, we checked whether the Ab(31-42) analogues were toxic themselves. The peptides were dissolved in a small amount of 60 mm NaOH, diluted to 50 mm with cell culture media, and added to differentiated PC-12 cells. Most of the analogues, with the exception of [N-Me-A1]Ab(31-42), showed no toxicity to the cells and even moderately increased cell viability relative to cells incubated with media alone, as assessed by the MTT assay (Figure 1 ). [25] Next, we screened the N-methylated Ab(31-42) derivatives for inhibition of Ab42-induced neurotoxicity in single-dose experiments. Differentiated PC-12 cells were incubated with Ab42 (5 mm) for 24 h in the absence or presence of a tenfold excess of each derivative, and cell viability was assessed using the MTT assay (Figure 2 To further evaluate the analogues, which were found to significantly increase inhibitory activity in the initial screen, we examined each peptide in both the MTT and LDH dose-response assays (Figure 3 a and 3 b, respectively) . We used both assays because they address different aspects of cell toxicity-the MTT assay measures mitochondrial activity of viable cells, whereas the LDH assay detects membrane integrity as a direct measurement of cell death. [26] Similarly to the parent peptide, the N-methylated Ab(31-42) analogues yielded dose-dependent inhibition of Ab42-induced toxicity (Figure 3) . The IC 50 values obtained are summarized in Table 2 . [N-Me-A3]Ab(31-42) had similar inhibitory activity to Ab(31-42), whereas the other three derivatives showed increased inhibitory activity. [NMe-A9]Ab(31-42) was the most potent analogue, yielding protection from Ab42-induced toxicity with an IC 50 value of 6 AE 1 mm in the MTT assay (threefold improvement relative to the parent peptide) and 7 AE 1 mm in the LDH assay (sixfold improvement).
N-Methyl substitutions with restoration of the original side chain
As the second step in our SAR strategy, to determine the contribution of the N-methylation versus the side chain change to the inhibitory activity, we synthesized analogues containing substitution of the original residue in positions found to affect biological activity significantly, by the N-Me version of these residues (Table 2 ). These included analogues substituted both at the four positions that yielded a significant increase in inhibitory activity (positions 3, 8, 9, and 11) and in the single position that caused increased toxicity (position 1).
The synthesis of the analogues containing N-methylation at positions 1, 9, and 11 was challenging because the original side chains in these positions are b-substituted (I 1, V 9 and I 11) causing substantial steric hindrance. Accordingly, we To prevent the degradation of these analogues, we neutralized the crude peptide immediately after cleavage using N,N-diisopropylethylamine (DIPEA). The conditions for the difficult synthesis of N-Me-A analogues described above were also necessary for the successful synthesis of these three analogues. In contrast, [N-Me-G3]Ab(31-42) was successfully synthesized using the general protocol described above and did not require DIPEA neutralization.
Filtration experiments showed that, similar to the N-Me-A analogues, the analogues substituted at positions 1 and 8 had low solubility, whereas substitutions at positions 3, 9, and 11 yielded peptides with high solubility (> 100 mm, Table 2 ). Cell viability assessment using the MTT assay revealed that N-methylation at positions 3, 8, 9, or 11 did not cause toxicity, whereas -42), suggesting that the toxicity was caused by the introduction of the N-Me group rather than the side chain change and might correlate with the increase in both basicity and hydrophobicity associated with conversion of the N-terminal primary amine into a secondary amine. Restoring the side chain in positions 3, 8, 9, or 11 had a relatively weak effect on the inhibitory activity (Table 2) , suggesting that the main cause for the increased inhibitory activity of these analogues was the introduction of the N-Me group, rather than the side chain substitution. the LDH assay, whereas in the MTT assay, we did not find a difference between the N-Me-A-and N-Me-V-containing analogues. 5. N-Methylation at position 11 increased the inhibitory activity, and the small side chain of A yielded peptides with better inhibition than those with the bulky hydrophobic side chain of I. 6. N-Methylation of residues previously shown to be in a bstrand conformation in Ab(31-42) increased the solubility of Ab(31-42) substantially. N-Methylation in the turn region or at the C-terminal residue was less effective in increasing solubility. N-Methylation at the N-terminal residue decreased the solubility. 7. The changes in inhibitory activity observed relative to the parent peptide were not merely a reflection of better solubility of certain analogues, but rather likely to reflect more efficient binding to Ab42 and/or disruption of particular toxic structures.
Due to the increased solubility of most of the N-methylated analogues, their synthesis was more facile relative to that of the parent peptide. Though in some cases protocol modifications were needed to overcome DKP formation, the changes were relatively simple and purification of the products by RP-HPLC was straightforward, in contrast to Ab(31-42). [21] There was no obvious pattern to predict which residue would be difficult to add as an N-Me amino acid. Previously, it was reported that bulky, hydrophobic N-methylated amino acids might pose challenges in coupling to a growing peptide, and in some cases even sterically unhindered N-methylated amino acids gave poor yields. [18] We found this to be the case in the synthesis of [N-Me-A8]Ab(31-42) and [N-Me-G8]Ab(31-42), both of which were obtained in low yield.
The mechanisms by which introduction of N-methylated amino acids prevents aggregation of amyloidogenic peptides and proteins were summarized in a Review by Sciarretta et al. [18] Replacement of an amide proton by a methyl group breaks hydrogen bonds among individual b-strands. In addition, the methyl group is larger than the amide proton and prevents the close approach of the peptide chains by steric hindrance. The same reasons likely improve peptide solubility upon introduction of N-Me amino acids. The replacement of an amide proton by a methyl group could break hydrogen bonds inside hydrophobic clusters or organized structures, allowing water molecules to insert between polypeptide chains and interact with the peptide backbone. N-Me groups could disrupt association of both intramolecular and intermolecular b-strands. In the case of Ab(31-42), if disruption occurs intramolecularly, the b-hairpin structure is destabilized and no bsheets form. In contrast, if the N-Me groups project outward, the b-hairpin conformation can still form, but the N-Me group would interfere with intermolecular b-sheet formation. Either way, self-association of the N-Me-substituted peptides and their association with full-length Ab42 are attenuated, resulting in increased aqueous solubility and inhibition of toxicity. Interestingly, Gordon et al. found that N-methylated Ab (16) (17) (18) (19) (20) analogues were highly soluble in both aqueous and organic solutions, suggesting that N-methylated peptides might be able to pass spontaneously through cell membranes, an important property for drug delivery, diagnostics, and inhibitory activity. [17] Previously, a coil-turn structure of certain Ab42 CTFs, including Ab(31-42), was found to correlate with the degree of inhibition of Ab42-induced toxicity, whereas a b-strand/b-turn conformation did not. [19, 24] We predicted that introduction of N-methylated amino acids would shift the equilibrium from bstrand/b-turn toward coil-turn, facilitating association of the N-methylated analogues with Ab42 that promote formation of a nontoxic assembly. The data suggest that these predictions were correct and imply that inhibition is achieved through specific interaction between particular analogues and Ab42.
Conclusions
Using a two-step N-methyl (N-Me) amino acid substitution strategy, we successfully increased both the aqueous solubility and the inhibitory activity of Ab(31-42). This two-step strategy is applicable to structure-activity relationship (SAR) studies of other hydrophobic/amyloidogenic peptides where the parent peptide is characterized by low solubility, and it could lead to the development of therapeutic agents for Alzheimer's and other amyloid diseases.
Experimental Section
Reagents ) were purchased from Novabiochem (Gibbstown, NJ, USA). Wang resin and all other reagents were obtained from Sigma-Aldrich (St. Louis, MO, USA) and were of the highest purity available. All commercially available solvents and reagents were used without further purification. High-purity water (18.2 MW) was obtained using a Milli-Q system (Millipore, Bedford, MA, USA).
Peptide synthesis: Synthesis, purification, and characterization of Ab42 were carried out as described previously. [27] Peptides were purified using reverse-phase high-performance liquid chromatography (RP-HPLC), and characterized by mass spectrometry (MS) and amino acid analysis (AAA).
General protocol for synthesis of N-methylated Ab(31-42) derivatives: Ab(31-42) and derivatives were synthesized using a Discover microwave-assisted synthesis system (CEM, Matthews, NC, USA). FMOC-protected, pre-loaded NovaSyn TGA resin (0.1 mmol) was placed in a peptide synthesis vessel, swollen in N,N-dimethylformamide (DMF), and deprotected with 20 % piperidine (or 4-methylpiperidine) in DMF (5 mL) for 20 min at RT. After washing with DMF (3 3 mL), a mixed solution of Fmoc-AA-OH (0.3 mmol), 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU, 0.3 mmol) and N,N-diisopropylethylamine (DIPEA, 0.6 mmol) in DMF (4 mL) was added to the reaction vessel. Fmoc-N-Me-A-OH and the following amino acid were coupled using 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU) as an activating reagent. The coupling reaction was performed using 40 W microwave energy for 8 min at 50 8C. A 2,4,6-trinitrobenzenesulfonic acid (TNBS) color test kit (TCI AMERI-CA, Portland, OR, USA) was applied to detect remaining free amino 520 www.chemmedchem.org groups. The coupling reaction efficacy was monitored by the formation of piperidine-dibenzofulvene (or 4-methylpiperidine-dibenzofulvene) using UV spectroscopy. [28] After completion of the sequence, the resin was thoroughly washed with DMF (3 3 mL) and then with CH 2 Cl 2 , dried under vacuum, and the peptide was cleaved using a 95:2.5:2.5 (v/v/v) mixture of trifluoroacetic acid (TFA)/1,2-ethanedithiol/H 2 O for 1.5 h at RT. The cleavage solution was collected, and its volume was reduced to 1-2 mL using a gentle stream of high-purity N 2 . Peptides were precipitated by addition of cold Et 2 O, purified by RP-HPLC, and characterized by MS and AAA. The purity of all peptides was higher than 95 %, as determined by analytical RP-HPLC. The peptide sequences, calculated masses, and observed masses are listed in Table 2 . ,0.5 g) was swollen in DMF and filtered. The first amino acid was attached by adding a mixture of Fmoc-N-Me-A-OH (0.4 mmol) and DIPEA (4 mmol) in DMF (3 mL). The mixture was shaken for 1 h at RT. Capping of excess reactive groups on the resin was achieved using a 17:2:1 (v/v/v) mixture of CH 2 Cl 2 /MeOH/ DIPEA. The resin was washed with CH 2 Cl 2 (3 3 mL), DMF (3 3 mL), and CH 2 Cl 2 (3 3 mL). The loading rate was tested using UV spectroscopy as described above. The following Fmoc-I-OH and Fmoc-V-OH were coupled with HATU as an activation reagent and with double coupling. The general protocols described above were followed for coupling and deprotection of other amino acids, and cleavage from the resin. The solution was collected, and its volume reduced to 1-2 mL using a gentle stream of high-purity N 2 . The peptide was precipitated by addition of cold Et 2 O and collected by centrifugation. After the Et 2 O was removed, the peptide was neutralized with DIPEA and washed with cold Et 2 O (2 10 mL). The crude peptide was immediately dissolved in H 2 O, frozen, lyophilized, and then purified using RP-HPLC. The fractions containing the pure peptide were frozen immediately and re-lyophilized.
Solubility: A solubility study was carried out as described previously. [19] Briefly, peptides were dissolved or suspended in 60 mm NaOH (10 % of the final volume) and then diluted with 10 mm NaH 2 PO 4 / Na 2 HPO 4 (pH 7.4) to a nominal concentration of 200 mm. The solution was sonicated for 1 min and then filtered through an Anotop 10 syringe filter with 20 nm pore size (Whatman, Florham Park, NJ, USA). Three to five replicates were measured for each peptide. The actual peptide concentrations were determined by AAA and the results are presented as the mean AE standard error of the mean (SEM).
Cell viability assays:
The methods for evaluation of the biological activity of the CTFs themselves and their inhibition of Ab42-induced toxicity were described previously. [10] Briefly, PC-12 cells were differentiated into a neuronal phenotype by incubation with nerve growth factor (50 ng mL
À1
) for 48 h. The cells then were incubated with solutions of Ab42 alone at 5 mm, Ab(31-42) analogues alone at 50 mm, or Ab42/Ab(31-42) analogue mixtures at a concentration ratio of 1:10, for 24 h. For initial screening of the new analogues, cell viability was determined by the MTT assay using a CellTiter 96 kit (Promega, Fitchburg, WI, USA). Negative controls included NaOH at the same concentration as in the peptide solutions and media alone. A positive control was 1 mm staurosporine for full kill, which was used to represent a 100 % reduction in cell viability, based on which the percentage viability of all of the experimental conditions was calculated. Active analogues were characterized further for dose-dependent activity. In these experiments, Ab42 alone and Ab42:Ab(31-42) analogue mixtures at concentration ratios of 1:0.1, 1:0.3, 1:1, 1:3, and 1:10 (and in some cases 1:20 and 1:30, according to peptide solubility) were used. Cell viability was measured using both the MTT assay and the LDH-release assay (CytoTox-ONE Homogenous Membrane Integrity Assay kit, Promega, Fitchburg, WI, USA). At least three independent experiments with five replicates (n ! 15) were performed. The results were averaged and presented as the mean AE SEM.
